Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Thursday 09 January, 2014

AstraZeneca PLC

US FDA Approval of Farxiga (dapagliflozin)

RNS Number : 2589X
AstraZeneca PLC
09 January 2014
 



 

ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE
US FDA APPROVAL OF FARXIGA™ (DAPAGLIFLOZIN)

 

AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGA™ (dapagliflozin).

 

See http://packageinserts.bms.com/pi/pi_farxiga.pdf for US Full Prescribing Information for FARXIGA.

 

The companies will provide additional details regarding the approval in a press release to follow.

 

About the AstraZeneca/Bristol-Myers Squibb Diabetes Alliance

Dedicated to addressing the global burden of diabetes by advancing individualised patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialise a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find out more about the Alliance and our commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com or www.bms.com.  

 

On 19 December 2013 AstraZeneca and Bristol-Myers Squibb announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance to consolidate worldwide ownership of the diabetes business within AstraZeneca.  The closing of the transactions contemplated by the agreement is subject to customary terms and conditions, and is expected to occur during the first quarter of 2014.  

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com. 

 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

 

 

CONTACTS

 

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Michele Meixell                            +1 302 885 2677 (US)

Jacob Lund                                  +46 8 553 260 20  (Sweden)

 

 

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor                           + 1 302 886 1842     mob:  +1 302 357 4882

Anthony Brown                            +44 20 7604 8067    mob: +44 7585 404943

Jens Lindberg                             +44 20 7604 8414    mob: +44 7557 319729

 

 

9 January 2014

 

-ENDS-

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REAKMGGMVLZGDZG

a d v e r t i s e m e n t